Tubulis
ID: 6724547Developer of a suite of antibody-drug conjugates to advance cancer treatments.
5
Funding Rounds
$451.5m
Money raised
Recent Funding Rounds
Overview
Developer of a suite of antibody-drug conjugates to advance cancer treatments.
- Website:
- Business model: B2B
- Headquarters: Munich
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Do***** Sc******** |
|
- | |
| Jo*** He*** |
|
- |
Funding
Funding series
Funding Series Analysis
The company Tubulis has raised a total of $436.3m in funding over 5 rounds.
Key Insights:
- Tubulis Series C Round, October 2025: $361m
- Tubulis Series B round, May 2022: $63m
- Tubulis Therapeutics Series A round, July 2020: $12.3m
- Tubulis Therapeutics Series A Funding Round July 2020: $13.5m
- Tubulis Therapeutics Grant July 2017: $1.67m
Industries
Tubulis is active in the following industries: